Shares in Agios Prescribed drugs (NASDAQ: AGIO) rose by 11.2% this week, placing the inventory into constructive territory for the yr. The transfer comes after a well-received first-quarter earnings report that confirmed sturdy progress in Aqvesme’s U.S. business launch. Administration additionally offered an replace on the progress of its pipeline, together with mitapivat for sickle cell illness (SCD) and tebapivat for Decrease-Threat Myelodysplastic Syndromes (MDS) and SCD.
Agios has a busy 2026 forward
The pharmaceutical firm already has mitapivat accepted to deal with hemolytic anemia in adults with Pyruvate Kinase (PK) deficiency underneath the model title Pyrukynd. It additionally has mitapivat, which was extra lately accepted within the U.S. to deal with grownup thalassemia underneath the model title Aqvesme, and the addition of Aqvesme gross sales (the primary quarter of full gross sales) helped gross sales develop to $20.7 million from simply $8.7 million in the identical quarter of 2025. Administration expects “very sturdy demand” for Aqvesme within the coming quarters.
|
Will AI create the world’s first trillionaire? Our group simply launched a report on a little-known firm, known as an “Indispensable Monopoly,” offering the essential expertise Nvidia and Intel each want. |
The place subsequent for Agios Prescribed drugs
As readers already knowthe corporate lately suffered a setback when a rival developer of a pyruvate kinase-R (PKR) activator, Novo Nordisk, reported top-line outcomes from a trial indicating that its drug, etavopivat, was superior to mitapivat in treating SCD. In a nutshell, etavopivat achieved each of its main endpoints in SCD, however mitapivat failed to fulfill considered one of them: lowering the annualized fee of ache disaster occasions.
It is unclear what the market potential for mitapivat (SCD) might be. Nonetheless, administration confirmed it was aligned with the Meals and Drug Administration (FDA) “on a path towards U.S. accelerated approval for mitapivat in sickle cell illness” with submitting anticipated within the second quarter.
That stated, buyers in all probability have larger hopes for its next-generation PKR, tebapivat, which administration confirmed could have Section 2 top-line outcomes out there in MDS within the first half of 2026, after which SCD within the second half of 2026. All informed, begin for Aqvesme, progress on mitapivat approval in SCD, and the hope of some constructive information on tebapivat make for an thrilling yr for the corporate.
Must you purchase inventory in Novo Nordisk proper now?
Before you purchase inventory in Novo Nordisk, think about this:
The Motley Idiot Inventory Advisor analyst group simply recognized what they imagine are the 10 best stocks for buyers to purchase now… and Novo Nordisk wasn’t considered one of them. The ten shares that made the reduce may produce monster returns within the coming years.
